ReviewPharmacogenomics
Genetic polymorphism associated with non-response to therapy in inflammatory bowel disease patients: a review.
Review in Pharmacogenomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Inflammatory bowel diseases: pathological mechanisms and therapeutic perspectives.Molecular biomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) poses a major therapeutic challenge due to its chronic course and variable treatment responses. Genetic polymorphisms significantly influence drug efficacy, prompting this review to analyze their role in treatment non-response. A systematic literature search (PubMed/Scopus) using terms like "genetic polymorphism," "non-response," and "IBD" identified 25 relevant studies. Key findings linked TNFα (-308 G > A), TNFRSF1A, and TNFRSF1B polymorphisms to reduced anti-TNFα therapy effectiveness. TPMT variants correlated with thiopurine toxicity, while CYP3A4 and CYP3A5 polymorphisms altered tacrolimus metabolism. These genetic markers could serve as predictive tools for personalized IBD treatment, emphasizing the potential of genetic screening in clinical practice. Future research should integrate multi-omics approaches to refine predictive models and advance precision medicine, ultimately improving patient outcomes through tailored therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.